Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adverum Biotechnologies (ADVM) Tops Q3 EPS by 1c
November 7, 2019 4:27 PM ESTAdverum Biotechnologies (NASDAQ: ADVM) reported Q3 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $180 thousand.
The third quarter was important for Adverum, as we reported sustained benefits from a single... More
